<DOC>
	<DOCNO>NCT01077986</DOCNO>
	<brief_summary>In study investigator want determine activity safety concurrent interruption MAPK PI3K pathways EGFR mTOR inhibition patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Everolimus , Cetuximab Capecitabine Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>This phase I/II non randomize single center study perform two step design . Part I dose find , whereby dose escalation perform everolimus capecitabine . Part II efficacy study . At MTD dos part II biomarker study perform blood tumor tissue . Study design phase I part : The first week patient treat everolimus alone . Capecitabine administer 14 day 3 weekly cycle , start day 8 . Cetuximab administer weekly , start day 8 . The dose fix cetuximab study treatment , whereas dos everolimus capecitabine differ per dose level . First dose level : Everolimus 5 mg daily continuously , Capecitabine 600 mg/m2 bid 2 week every 3 week , Cetuximab 400mg/m2 ( 120 min infusion ) first dose , thereafter 250 mg/m2 ( 60 min infusion ) weekly . Second dose level : Everolimus 10 mg daily continuously , Capecitabine 600 mg/m2 bid 2 week every 3 week , Cetuximab 400mg/m2 ( 120 min infusion ) first dose , thereafter 250 mg/m2 ( 60 min infusion ) weekly . Third dose level : Everolimus 10 mg daily continuously , Capecitabine 800 mg/m2 bid 2 week every 3 week , Cetuximab 400mg/m2 ( 120 min infusion ) first dose , thereafter 250 mg/m2 ( 60 min infusion ) weekly . Study design phase II part At MTD 14-25 patient pancreatic cancer include . In phase II part , everolimus administer one week start cetuximab . At day 8 first dose cetuximab administer . Capecitabine start one week thereafter . This enable u perform pharmacodynamic study assess biomarker change different phase treatment . Everolimus administer continuously dose 5 10 mg orally daily ( dependent MTD part 1 ) . Capecitabine administer orally dose 400 - 800 mg/m2 twice daily 14 day follow one week rest ( dependent MTD part 1 ) . Patients receive cetuximab infusion via infusion pump , initial dose 400 mg/m² ( 120 min ) subsequent weekly infusion 250 mg/m² ( 60 min ) , start day 8 .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed informed content obtain prior treatment Cytological histological confirm adenocarcinoma pancreas Metastatic pancreatic cancer Measurable lesion accord RECIST criterion ECOG/ WHO performance 02 Age &gt; 18 year Life expectancy &gt; 3 month Adequate renal function ( creatinine &lt; 150 µmol/L ) Adequate liver function ( bilirubin &lt; 1.5 time upper limit normal , ALAT ASAT &lt; 5.0 time upper limit normal case liver metastases &lt; 2.5 upper limit normal absence liver metastasis Adequate bone marrow function ( WBC &gt; 3.0 x 10 9/L , platelet &gt; 100 x 10 9/L ) Mentally , physically , geographically able undergo treatment follow Clinical radiological evidence CNS metastases Pregnancy ( positive serum pregnancy test ) lactation Serious concomitant systemic disorder would compromise safety patient , discretion investigator Patients severe and/or uncontrolled medical condition Previous treatment mTOR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>mTOR inhibition</keyword>
	<keyword>EGFR inhibition</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>